Clinical Trials

DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung

NCT04137900 2024-02-05

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Phase 1 Recruiting

499 enrolled

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Neoplasm Metastasis

NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Phase EARLY_PHASE1 Unknown

40 enrolled

EGFR Positive Non-small Cell Lung Cancer

NCT06065813 2023-10-04

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Phase 2 Recruiting

20 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05962021 2023-08-01

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

126 enrolled

Phase 2 Not yet recruiting

Non Squamous Non Small Cell Lung Cancer

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Phase 1 Unknown

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

124 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent

NCT05800340 2023-04-05

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Phase 1 Completed

27 enrolled

High-Risk Resectable NSCLC

NCT03856411 2023-02-01

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Phase 3 Completed

465 enrolled

Treatment-naive Advanced Non-small Cell Lung Cancer

NCT05162196 2022-05-02

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

57 enrolled

Small Cell Lung Carcinoma

NCT05055583 2021-09-24

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04304248 2021-05-06

NeoTAP01

Carcinoma, Non-Small-Cell Lung

NCT04725448 2021-04-06

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

27 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Thoracic Neoplasms

NCT04797702 2021-03-15

CT32

Phase 1/2 Unknown

67 enrolled

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04713761 2021-01-26

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

15 enrolled

Mesothelioma, Malignant

NCT04613804 2020-11-03

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

Carcinoma, Non-Small-Cell Lung

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

60 enrolled

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT03904719 2020-07-09

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

Small Cell Lung Carcinoma

NCT04193098 2020-07-07

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

Phase 1 Unknown

10 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

20 enrolled